Loading
Viennese surgical oncologist who presides over the ABCSG and has led landmark adjuvant breast cancer trials such as ABCSG-12, ABCSG-18 and PALLAS.
Michael Gnant is President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and a professor of surgery at the Medical University of Vienna's Comprehensive Cancer Center. He has led major academic trials in early breast cancer, including studies of adjuvant zoledronic acid and denosumab and the PALLAS trial of adjuvant palbociclib, shaping international treatment standards.
| Title | Journal | Year |
|---|---|---|
| Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) | Journal of Clinical Oncology | 2022 |
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares Austrian Breast & Colorectal Cancer Study Group, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.